Cited by 110Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedicinal Plants and Neuroprotection

Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study

Open access
Lim, Yen Ying, Villemagne, Victor L., Laws, Simon M., Ames, David, Pietrzak, Robert H., Ellis, Kathryn A., Harrington, Karra, Bourgeat, Pierrick +6 more·2014·PLoS ONE

Abstract

OBJECTIVE: Cross-sectional genetic association studies have reported equivocal results on the relationship between the brain-derived neurotrophic factor (BDNF) Val66Met and risk of Alzheimer's disease (AD). As AD is a neurodegenerative disease, genetic influences may become clearer from prospective study. We aimed to determine whether BDNF Val66Met polymorphism influences changes in memory performance, hippocampal volume, and Aβ accumulation in adults with amnestic mild cognitive impairment (aMCI) and high Aβ. METHODS: Thirty-four adults with aMCI were recruited from the Australian, Imaging, Biomarkers and Lifestyle (AIBL) Study. Participants underwent PiB-PET and structural MRI neuroimaging, neuropsychological assessments and BDNF genotyping at baseline, 18 month, and 36 month assessments. RESULTS: In individuals with aMCI and high Aβ, Met carriers showed significant and large decline in episodic memory (d = 0.90, p = .020) and hippocampal volume (d = 0.98, p = .035). BDNF Val66Met was unrelated to the rate of Aβ accumulation (d = -0.35, p = .401). CONCLUSIONS: Although preliminary due to the small sample size, results of this study suggest that high Aβ levels and Met carriage may be useful prognostic markers of accelerated decline in episodic memory, and reductions in hippocampal volume in individuals in the prodromal or MCI stage of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0086498

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • High Aβ and BDNF Val66Met polymorphism in prodromal AD are linked and suggested as important prognostic markers of increased memory decline and hippocampal atrophy.

    “While increased memory decline and hippocampal atrophy have been reported previously in adults with an MCI and high Aβ, Lim et al., (2014) provided a preliminary report and linked high Aβ and BDNF Val66Met polymorphism in prodromal AD suggesting them as important prognostic markers of increased memory decline and hippocampal atrophy [73].”
  • BDNFMet carriers exhibited greater memory decline and hippocampal atrophy over 36 months compared to BDNF Val homozygotes.

    “In another study, BDNFMet carriers exhibited greater memory decline and hippocampal atrophy in a span of 36 months compared to BDNF Val homozygotes.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K., Bourgeat, P., Bush, A. I., Martins, R. N., Masters, C. L., Rowe, C. C., Maruff, P., & for the AIBL Research Group
Affiliations
  • The University of Melbourne (AU)
  • Edith Cowan University (AU)
  • Yale University (US)
  • Australian e-Health Research Centre (AU)
Corresponding author
Lim, Yen Ying
Venue
PLoS ONE
Published
2014-01-27
Volume
9
Issue
1
Pages
e86498
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2035761246
Cited by
110
References
33
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 8 · 2022: 4 · 2021: 11 · 2020: 14 · 2019: 10 · 2018: 9 · 2017: 14 · 2016: 12 · 2015: 14 · 2014: 5
FWCI
11.45
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
  • Australasian Journal of Paramedicine (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion)
  • Swinburne figshare (Swinburne University of Technology) (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Science and Industry Endowment Fund
  • Australian Government
  • Edith Cowan University
  • Dementia Collaborative Research Centres, Australia
  • Elan
  • H. Lundbeck A/S
  • Avid Radiopharmaceuticals
  • Medical Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords
BDNF Val66Met polymorphism, brain-derived neurotrophic factor, prodromal Alzheimer's disease, amnestic mild cognitive impairment, episodic memory decline, hippocampal atrophy, hippocampal volume, amyloid-beta deposition, genetic risk factors, prognostic factors
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Atrophy, Australia, Cross-Sectional Studies, Female, Genotype, Hippocampus, Humans, Magnetic Resonance Imaging, Male, Memory Disorders, Amyloid beta-Peptides, Brain-Derived Neurotrophic Factor, Mutation, Missense, Positron-Emission Tomography, Genetic Association Studies, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review